Who We Are
Going Beyond Binding for Protein Drug Discovery
The current state-of-the-art method for screening protein drugs is phage display, which identifies candidate proteins that bind specified targets. Such binding centric drug discovery is limited by assumptions about the correct drug target, and the premise that binding equals activity.
Our approach enables activity-based discovery of protein drugs within intact signaling networks in living cells. Simply put, we find drugs that affect the targeted network underlying a disease, which requires less a priori knowledge. Using this method, we build drug discovery pipelines before disease pathways are comprehensively understood, which can take decades to achieve. We have the potential to speed up therapeutic discovery and yield promising drugs that cannot be found through binding centric screening.
Meet the Team
We’re a passionate team relentlessly working towards advancing protein drug discovery
Doug’s academic career initially focused on understanding the molecular mechanisms behind signaling networks and cell behavior. He was an integral team member in the DARPA Rapid Threat Assessment project at The University of Colorado, Boulder, where he gained expertise in proteomics, metabolomics, and phenotypic microscopy screening. He has also authored over 16 academic research publications.
Karen is a business administrator and project manager who has developed skills in several different industries including non-profits that study climate change and travel organizations. She manages our day-to-day business operations and projects including website and social media management, inventory management, and accounting.
Jeremy operates at the intersection of mechanical and electrical engineering and data analysis with an emphasis on biological data sets. Prior to joining BioLoomics, he was an analyst for the DARPA Rapid Threat Assessment project at the University of Colorado, Boulder. He specializes in large multidimensional datasets and has applied this expertise to proteomics, metabolomics, and microscopy data.
Ted has over 10 years of biotech industry experience, specializing in Manufacturing Science and Technology (MSAT). He has held process development and engineering positions at several industry-leading pharmaceutical companies. Ted relocated to Colorado from California to lead the effort to streamline, standardize, and scale up BioLoomics’ research and development.
Bill is a pharma and biotech veteran who joined BioLoomics in 2021. Prior to that he was CEO at NeuroLucent, a start-up focused on Alzheimer’s. Bill is also CSO at Life Science Nation (LSN), which offers fund-raising services to early-stage companies. Prior to LSN, Bill was a BD executive at AbbVie where he led a global scouting team. Earlier in his career, he directed drug discovery programs in oncology, antivirals and antibacterials.
Mike is an experienced research biochemist coming from ArcherDX and Sartorius with expertise in developing high throughput assays for cell screening using a variety of techniques including NGS, microscopy, and flow cytometry. During his postdoctoral and graduate work at the University of Colorado Boulder, he studied the immune response to bacterial infection using FRET biosensors in primary macrophages. Mike is focused on bringing the drug discovery and downstream analysis of candidates to scale.
Dr. Church has made numerous advancements in protein and genome engineering and genome sequencing and is often referred to as the father of synthetic biology. His support of translational biotech is unrivaled in the academic community. His advice will bolster our ability to navigate the fitness landscape of protein designs and best utilize the high throughput deep mutational scanning features of our ‘Evolution in a Microscope’ platform.
Viswa is the CEO and founder of Enveda Biosciences, which is leveraging machine learning, metabolomics, and knowledge graphs to mine the world’s natural products for novel therapeutics. Previously, he was an early driver at Recursion Pharmaceuticals, where he fueled technological development during Recursion’s rapid growth phase.
Aaron Sato is the CSO of Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform. Dr. Sato’s support will help BioLoomics strengthen its strategy to ‘mine’ biosensing drugs using its ‘Evolution in a Microscope’ technology.
Michael is a professor at University of Colorado, Boulder in the department of Molecular, Cellular and Developmental Biology. He is a biophysicist with expertise in the structural biology of channels and receptors. He is a co-founder of InRedox and a co-founder and CSO of AmideBio. Michael joined the BioLoomics Scientific Advisory Board in 2021 and helps guide our decisions in performing targeted saturation mutagenesis of protein drugs to enhance specificity and efficacy.
